Biotechnology

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...

2024-02-19 08:20 1463

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...

2024-02-18 20:50 1703

New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC

 - A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...

2024-02-16 22:03 2194

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...

2024-02-15 17:05 1696

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...

2024-02-15 16:05 1670

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...

2024-02-15 11:37 1271

YS Biopharma Announces Appointment of New Directors

GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...

2024-02-14 20:50 3336

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...

2024-02-14 08:07 3527

Ajinomoto Co. Launches Silicon Valley CVC HQ to Grow U.S. Investments, Adds New Portfolios

TOKYO, Feb. 13, 2024 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co."), the Japan-based multinational corporation covering food, healthcare and electronic materials, and built on "AminoScience," (*) has expanded its corporate venture capital (CVC) arm with new U.S. headquarters to grow its in...

2024-02-13 14:00 1387

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive  Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...

2024-02-13 03:26 3667

Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

* Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in space * Dr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory Board ...

2024-02-09 22:44 2467

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and th...

2024-02-09 19:30 6005

UFC WORLD CHAMPION JON JONES, LIFECYKEL LABS, CANTERBURY-BANKSTOWN BULLDOGS AND BETTER BREATHING DEVICES HOST ELITE PERFORMANCE/TRAINING DAY

SYDNEY, Feb. 9, 2024 /PRNewswire/ -- Jon Jones, UFC world champion and arguably the best MMA fighter to have ever existed is touringAustralia and has teamed up with Lifecykel Labs to host and facilitate a best-in-class performance training day which was held at the Canterbury-Bankstown Bulldogs h...

2024-02-09 18:09 2966

Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab

BENGALURU, India, Feb. 9, 2024 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, ...

2024-02-09 11:22 2180

Cathay Biotech and 3P.COM Signed Joint Venture Agreement to Propel Sustainable Composite Innovations

China's Cathay Biotech Inc. and South Korea's 3P.COM Co. Limited signed an agreement to establish a joint venture, targeting the development of bio-based polyamide thermoplastic composites.  SHANGHAI, Feb. 8, 2024 /PRNewswire/ -- Cathay Biotech Inc. ("Cathay") and 3P.COM Co. Limited ("3P.COM") s...

2024-02-08 23:00 1557

E-Home Household Services Holdings Limited's subsidiary Zhongrun Pharmaceutical intends to acquire NBL (New Zealand) Limited to help expand the international market

FUZHOU, China, Feb. 8, 2024 /PRNewswire/ -- E-Home Household Services Holdings Limited (NASDAQ:EJH) (the "Company" or "eHome"), an integrated home services provider inChina, announced that its subsidiary, Zhongrun (Fujian) Pharmaceutical Co., Ltd, intends to acquire NBL (New Zealand) Limited ("NB...

2024-02-08 22:00 4457

Tianlong's New Launch Gentier X3 Made its Appearance at Medlab Middle East 2024

DUBAI, UAE, Feb. 8, 2024 /PRNewswire/ -- The 4-day Medlab Middle East 2024 at the Dubai World Trade Center came to an end successfully onFebruary 8. MedLab is the largest exhibition of medical equipment in theMiddle East region, attracting visitors worldwide to experience the academic atmosphere ...

2024-02-08 21:00 2602

MGI Named a Finalist in the 2024 Edison Awards™ for Innovative DNBSEQ-T20x2* Gene Sequencer

SHENZHEN, China, Feb. 8, 2024 /PRNewswire/ -- MGI Tech , a company committed to building core tools and technology to lead life science, today announced its nomination as a finalist for the2024 Edison Awards™  in the "Health, Medical ...

2024-02-08 21:00 1412

First in Human Dosed in Clinical Trial of ZMA001 for Treatment of Pulmonary Arterial Hypertension (PAH)

INCHEON, South Korea, Feb. 7, 2024 /PRNewswire/ -- Zymedi announced today that the first in human dosage of ZMA001, a monoclonal antibody being developed as a first-in-class treatment for Pulmonary Arterial Hypertension (PAH) has been initiated. The placebo-controlled phase 1 trial designed to a...

2024-02-08 11:53 1308

Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT

Companies will work together to offer fast, cost-effective ultra-high-throughput library preparation workflows SAN JOSE, Calif. and BEVERLY, Mass., Feb. 7, 2024 /PRNewswire/ -- Complete Genomics, a life sciences company specializing in end-to-end DNA sequencin...

2024-02-07 22:00 1296
1 ... 567891011 ... 275

Week's Top Stories